Never mind; I found it:
from http://www.reuters.com/article/idCNN1317966020100914?rpc=44
Sales could reach $125 million by 2015 if it wins the additional approval, said Steve Yoo, an analyst for Leerink Swann Research.
Net sales from Vivitrol were $20.2 million for fiscal 2010, compared with $16.9 million for 2009 for Alkermes and its then-partner Cephalon Inc (CEPH.O), according to Alkermes.
But it costs the company roughly $40 million to make and sell the drug, said Leerink's Yoo.
"Therefore, the opioid dependence indication is critical for commercial success," he added.